Andrew J. Barkmeier, MD

associate professor of ophthalmology and vitreoretinal surgery at Mayo Clinic in Rochester, Minnesota

Articles by Andrew J. Barkmeier, MD

Q&A: Andrew J. Barkmeier, MD, on the risk of sight-threatening diabetic retinopathy with GLP-1 RA use

ByAndrew J. Barkmeier, MD,Sydney M Crago,Martin David Harp

August 22nd 2025

Research reveals that GLP-1 medications, including semaglutide, do not increase diabetic retinopathy risks, offering reassurance for patients and prescribers.

Latest Updated Articles

Q&A: Andrew J. Barkmeier, MD, on the risk of sight-threatening diabetic retinopathy with GLP-1 RA use
Published: August 22nd 2025 | Updated:

Andrew J. Barkmeier, MD

Articles by Andrew J. Barkmeier, MD

Q&A: Andrew J. Barkmeier, MD, on the risk of sight-threatening diabetic retinopathy with GLP-1 RA use

Latest Updated Articles

Trending on Modern Retina

Increasing the knowledge base of GA is key to individualizing patient therapy

Quantifying Intermittent Retinal Capillary Perfusion in RVO and PDR

AAO debuts technician training platform ahead of 2025 meeting